Foghorn Therapeutics Inc. insider trading
Every open-market purchase and sale by Foghorn Therapeutics Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Foghorn Therapeutics Inc.’s insiders pay?
From August 18, 2023 to March 12, 2024, 2 insiders reported 0 open-market purchases and 2 sales not made under a pre-set plan in Foghorn Therapeutics Inc. After sales, the shares moved −37.1% against the index over 12 months (a negative figure means selling was the right call).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Agresta Samuel | Chief Medical Officer | 0 | — | — | 1 | −30.9% (1) | August 18, 2023 |
| Cavalie Fanny | Chief Strategy/Bus Ops Officer | 0 | — | — | 1 | −43.3% (1) | March 12, 2024 |